-
cgSHAPE-seq Maps SARS-CoV-2 Chimera Binding Sites
2026-09-18
The reference preprint introduces cgSHAPE-seq, a chemical-guided sequencing method that maps RNA-ligand contacts at single-nucleotide resolution. Applied to SARS-CoV-2 5′ untranslated region SL5, the approach identified a bulged guanosine recognized by coumarin derivative C30 and guided the development of RNA-degrading chimeras, including C64.
-
Lypressin Acetate: From Receptor Biology to Translation
2026-09-18
Lypressin acetate, also known as Lysine vasopressin acetate, offers translational researchers a rare opportunity to connect vasopressin receptor pharmacology with antidiuretic, vascular, hemostatic, and emerging antiviral questions. This thought-leadership analysis explains how to design fit-for-purpose assays, interpret activity data, position the peptide against other vasopressin analogs, and assess the maturity of its potential SARS-CoV-2 RdRp inhibitor hypothesis without confusing preliminary findings with clinical evidence.
-
Piezo1, Caspase-8, and Cardiac PANoptosis
2026-09-17
The reference study identifies Piezo1 as a mechanosensitive driver of myocardial ischaemia/reperfusion injury and links its activity to caspase-8-mediated cardiomyocyte PANoptosis. Its combination of cardiac injury models, pharmacological modulation, calcium measurements, and mechanistic interaction analysis provides a framework for separating channel activity from downstream cell-death signaling.
-
From Antimycobacterial SAR to Smarter PEGylation
2026-09-17
A translational strategy for connecting medicinal chemistry, amide-linked lipid architectures, and delivery-system development using DMG-PEG2000-NH2 without overstating evidence.
-
Valemetostat: Dual EZH1/2 Inhibition in ATL
2026-09-16
The reference paper explains why simultaneous EZH1 and EZH2 inhibition is a rational epigenetic strategy for adult T-cell leukemia/lymphoma (ATL), where both enzymes can sustain H3K27me3-mediated transcriptional repression. It also summarizes the phase 2 evidence supporting valemetostat, including a 48.0% overall response rate in relapsed or refractory ATL, while highlighting the need for larger comparative studies.
-
Vasopressin Analogues: Evidence and Research Implications
2026-09-15
Glavaš and colleagues review how vasopressin structure, receptor biology, and peptide engineering have produced analogues with differentiated antidiuretic, vasoconstrictive, and therapeutic profiles. The analysis is especially useful for designing receptor-aware assays and for separating established clinical applications from emerging antiviral hypotheses.
-
Lypressin Acetate: A Translational Peptide Playbook
2026-09-15
Lypressin acetate connects vasopressin receptor pharmacology with practical translational workflows spanning diabetes insipidus, vasoconstriction research, and an emerging SARS-CoV-2 RdRp inhibitor hypothesis. This article outlines how to validate mechanism, manage assay risk, and position lysine vasopressin acetate beyond the limitations of a conventional product page.
-
From ROS Signal to Translational Confidence
2026-09-14
Reactive oxygen species measurements are most valuable when fluorescence is connected to mechanism, controls, and translational decisions. This article examines how DCFH-DA-based live-cell analysis can strengthen oxidative stress studies, using recent PM2.5-induced COPD findings involving Nrf2 and EGFR/PI3K/AKT signaling as a strategic model.
-
Acridine Orange hydrochloride: Practical Staining Guide
2026-09-14
Acridine Orange hydrochloride supports membrane-permeable differential staining of DNA, RNA, and single-stranded nucleic acids for cytochemical and flow-based assays. It is appropriate for validated cell cycle analysis, apoptosis detection, and nucleic acid profiling, but not for non-nucleic-acid targets or long-term storage of prepared solutions.
-
MG-132 (Z-LLL-al): Mechanism and Use
2026-09-13
MG-132, also called Z-LLL-al, is a cell-permeable peptide aldehyde that inhibits proteasome activity and supports apoptosis assay, cell cycle arrest, and oxidative stress studies. Its reported biochemical potency is approximately 100 nM for proteasome inhibition, while cellular effects depend on cell type, exposure conditions, and assay design.
-
Firefly Luciferase mRNA: Delivery-to-Signal QC
2026-09-12
Firefly Luciferase mRNA can serve as more than a reporter: it can reveal where an mRNA delivery workflow succeeds or fails. This article connects Cap1 and 5-moUTP design with practical stress-testing principles from recent LNP nebulization research.
-
MitMAB (B7620) for Reliable Endocytosis Assays
2026-09-12
MitMAB (SKU B7620) offers a practical, mechanism-focused way to test dynamin-dependent uptake in cell, organoid, and membrane-trafficking experiments. This guide connects published intestinal stem cell model findings with solvent selection, viability controls, protocol parameters, and evidence-based product evaluation.
-
AY 9944 dihydrochloride DHCR7 Workflow
2026-09-11
Build controlled DHCR7 inhibition experiments that connect 7-dehydrocholesterol accumulation with cholesterol, membrane-raft, and immune phenotypes. This guide separates reversible chemical perturbation from dhcr7 gene disruption and translates recent antiviral genetics into practical assay controls.
-
Podophyllotoxin Workflows for Cancer Research
2026-09-11
Build reproducible microtubule-perturbation assays with Podophyllotoxin, from solvent preparation and cell-cycle profiling to apoptosis and autophagy validation. The workflow also translates recent multidrug-resistance findings into practical assay controls without confusing parent compound activity with derivative-specific mechanisms.
-
Lypressin acetate: Assay Workflows and Use Cases
2026-09-10
Build receptor-resolved, stability-aware workflows around Lypressin acetate for antidiuretic, vasoconstriction, and antiviral screening. This guide connects practical assay design with quantified product attributes while separating established pharmacology from emerging SARS-CoV-2 research.